ASCO GU 2019: Preliminary results from a phase II GALAHAD study in adults with metastatic castration-resistant prostate cancer and DNA repair pathway defects
This study evaluated niraparib, which is a poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with metastatic…